Evidence of efficacy - Global Campaign against Headache
Evidence of efficacy
Evidence of efficacy
To improve the evidence base for headache treatments, we work with the Pain, Palliative and Supportive Care (PaPaS) Group of the Cochrane Collaboration, fostering systematic reviews of treatments for headache.
One of the purposes is to be able to advise WHO on revisions to their essential medicines list which, in time, will encourage availability worldwide of the drugs most needed to treat headache effectively. The Global Campaign is collecting and submitting evidence to WHO for this purpose. The list has the subject heading "Migraine", but other headache disorders are not currently represented. Currently, for acute therapy, it includes only acetylsalicylic acid, paracetamol and ibuprofen for children. Propranolol is the only drug listed for migraine prophylaxis.
The Norwegian National Headache Centre conducts controlled clinical trials of headache treatments.
Collaborators:
- S Derry, Pain, Palliative and Supportive Care (PaPaS) Group, Cochrane Collaboration, Oxford, UK
- R Gray, Duke University, Durham NC, USA
- G Kulkarni, National Institute for Mental Health and Neurosciences (NIMHANS), Bangalore, India
- A Moore, Pain, Palliative and Supportive Care (PaPaS) Group, Cochrane Collaboration, Oxford, UK
- GN Rao, National Institute for Mental Health and Neurosciences (NIMHANS), Bangalore, India
- P Tfelt‐Hansen, Danish Headache Centre, Glostrup Hospital, Glostrup, Denmark